Metabolic signatures of cultured human adipocytes from metabolically healthy versus unhealthy obese individuals

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Böhm, Anja ^a,b,c   Halama, Anna ^a   Meile, Tobias ^b   Zdichavsky, Marty ^b   Lehmann, Rainer ^b,c   Weigert, Cora ^a,b,c   Fritsche, Andreas ^b,c   Stefan, Norbert ^b,c   Königsrainer, Alfred ^b   Häring, Hans Ulrich ^a,b,c   De Angelis, Martin Hrabě ^a,c,d   Adamski, Jerzy ^a,c,d   Staiger, Harald ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY EICOSATETRAENOIC ACID; AMINO ACID; ARACHIDONIC ACID; ASPARTIC ACID; DOCOSAHEXAENOIC ACID; GLUTAMINE; HEXOSE; HISTIDINE; INSULIN; PHOSPHATIDYLCHOLINE; SPERMIDINE; UNCLASSIFIED DRUG; ARACHIDONIC ACID DERIVATIVE;

ADIPOCYTE; ADULT; AGE; ARTICLE; BODY FAT; BODY MASS; CAUCASIAN; CELL DIFFERENTIATION; CELL ISOLATION; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID TRANSPORT; MALE; METABOLITE; METABOLOMICS; MORBID OBESITY; OBESITY; PHOSPHOLIPID SYNTHESIS; SEX DIFFERENCE; SUBCUTANEOUS FAT; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADIPOCYTES; ADULT; ARACHIDONIC ACIDS; CELLS, CULTURED; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY, MORBID;

EID: 84898915968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093148     Document Type: Article

References (44)

1. Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nature reviews Endocrinology 9: 144-152.
2. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nature reviews Immunology 11: 85-97.
3. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, et al. (2008) Identification and characterization of metabolically benign obesity in humans. Archives of internal medicine 168: 1609-1616.
4. McLaughlin T, Abbasi F, Lamendola C, Reaven G (2007) Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Archives of internal medicine 167: 642-648. (Pubitemid 46598455)
5. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. Journal of the American College of Cardiology 59: 635-643.
6. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European heart journal 28: 88-136. (Pubitemid 46137814)
7. Oberbach A, Bluher M, Wirth H, Till H, Kovacs P, et al. (2011) Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. Journal of proteome research 10: 4769-4788.
8. Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, et al. (2010) Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 5: e13953.
9. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, et al. (2011) A genome-wide association study of metabolic traits in human urine. Nat Genet 43: 565-569.
10. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. (2011) Metabolite profiles and the risk of developing diabetes. Nature medicine 17: 448-453.
11. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, et al. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell metabolism 9: 311-326.
12. Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, et al. (2013) Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic Fatty liver. Diabetes care 36: 2331-2338.
13. Zhao X, Fritsche J, Wang J, Chen J, Rittig K, et al. (2010) Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6: 362-374.
14. Lucio M, Fekete A, Weigert C, Wagele B, Zhao X, et al. (2010) Insulin sensitivity is reflected by characteristic metabolic fingerprints - a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS One 5: e13317.
15. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, et al. (2012) Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 8: 615.
16. Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, et al. (2010) Insulin-sensitive obesity. American journal of physiology Endocrinology and metabolism 299: E506-515.
17. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes care 22: 1462-1470. (Pubitemid 29418240)
18. Schling P, Mallow H, Trindl A, Loffler G (1999) Evidence for a local renin angiotensin system in primary cultured human preadipocytes. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 23: 336-341.
19. Römisch-Margl W PC, Bogumil R, Röhring C, Suhre K, Adamski J (2012) Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics 8: 133-142. Doi:10.1007/s11306-011-0293-4
20. Zukunft S SM, Prehn C, Möller G, Adamski J (2013) Targeted Metabolomics of Dried Blood Spot Extracts. Chromatographia. Doi: 10.1007/s10337-013-2429-3.
21. Moller T (2012) Formation and paleoclimatic interpretation of a continuously laminated sapropel S5: a window to the climate variability during the Eemian interglacial in the Eastern Mediterranean http://nbn-resolving.de/ urn:nbn:de:bsz:21-opus-63524.pp. 46.
22. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, et al. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49: 1374-1380. (Pubitemid 30624239)
23. Nieuwdorp M, Stroes ES, Meijers JC, Buller H (2005) Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 5: 155-159. (Pubitemid 40378746)
24. Van De Craen B, Declerck PJ, Gils A (2012) The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thrombosis research 130: 576-585.
25. Iwaki T, Urano T, Umemura K (2012) PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157: 291-298.
26. Weijers RN (2012) Lipid composition of cell membranes and its relevance in type 2 diabetes mellitus. Curr Diabetes Rev 8: 390-400.
27. Stefan N, Peter A, Cegan A, Staiger H, Machann J, et al. (2008) Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 51: 648-656.
28. Obukowicz M, Welsch D, Salsgiver W, Martin-Berger C, Chinn K, et al. (1999) Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. Lipids 34 Suppl: S149. (Pubitemid 29323173)
29. Corey EJ, Shih C, Cashman JR (1983) Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 80: 3581-3584. (Pubitemid 13063121)
30. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, et al. (2011) Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 50: 115-131.
31. Nugent C, Prins JB, Whitehead JP, Wentworth JM, Chatterjee VK, et al. (2001) Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane. Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor gamma. The Journal of biological chemistry 276: 9149-9157.
32. Massiera F, Saint-Marc P, Seydoux J, Murata T, Kobayashi T, et al. (2003) Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? J Lipid Res 44: 271-279. (Pubitemid 37287770)
33. Malipa AC, Meintjes RA, Haag M (2008) Arachidonic acid and glucose uptake by freshly isolated human adipocytes. Cell biochemistry and function 26: 221-227. (Pubitemid 351373970)
34. Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, et al. (2012) Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. The Journal of clinical endocrinology and metabolism 97: 1695-1701.
35. Madsen L, Petersen RK, Sorensen MB, Jorgensen C, Hallenborg P, et al. (2003) Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. The Biochemical journal 375: 539-549. (Pubitemid 37433502)
36. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, et al. (2010) 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. Molecular pharmacology 77: 171-184.
37. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, et al. (2001) 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer research 61: 497-503. (Pubitemid 32128606)
38. Cole BK, Morris MA, Grzesik WJ, Leone KA, Nadler JL (2012) Adipose tissue-specific deletion of 12/15-lipoxygenase protects mice from the consequences of a high-fat diet. Mediators Inflamm 2012: 851798.
39. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC (2005) Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. European journal of pharmacology 513: 145-150.
40. Stunes AK, Reseland JE, Hauso O, Kidd M, Tommeras K, et al. (2011) Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes, obesity & metabolism 13: 551-558.
41. Gaster M, Nehlin JO, Minet AD (2012) Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: marker or maker of the diabetic phenotype? Archives of physiology and biochemistry 118: 156-189.
42. Schrauwen P, Hesselink MK (2008) Reduced tricarboxylic acid cycle flux in type 2 diabetes mellitus? Diabetologia 51: 1694-1697.
43. Egan JM, Henderson TE, Bernier M (1995) Arginine enhances glycogen synthesis in response to insulin in 3T3-L1 adipocytes. The American journal of physiology 269: E61-66.
44. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, et al. (2012) Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach. Diabetes.